ORAMED PHARMACEUTICALS INC.: depreciation expense

What this measure means

Depreciation recognized for the period under this concept. It is a noncash allocation of asset cost and may exclude amortization and depletion reported elsewhere.

Exact concept: us-gaap:Depreciation. Each value covers an annual-duration reporting interval, shown with both start and end dates. Different units remain separate; no currency conversion or interpolation is applied.

Coverage of this history

Selected reporting periods run from 2010-09-01 to 2025-12-31. The SEC response was captured on 2026-09-20.

Selected filing history

Related financial histories

• ORAMED PHARMACEUTICALS INC.: total assets
• ORAMED PHARMACEUTICALS INC.: stockholders equity
• ORAMED PHARMACEUTICALS INC.: cash and cash equivalents
• ORAMED PHARMACEUTICALS INC.: net income or loss
• ORAMED PHARMACEUTICALS INC.: operating cash flow
• ORAMED PHARMACEUTICALS INC.: capital expenditure payments
• ORAMED PHARMACEUTICALS INC.: revenue
• ORAMED PHARMACEUTICALS INC.: financing cash flow
• ORAMED PHARMACEUTICALS INC.: investing cash flow
• ORAMED PHARMACEUTICALS INC.: retained earnings or deficit
• ORAMED PHARMACEUTICALS INC.: basic weighted-average shares
• ORAMED PHARMACEUTICALS INC.: diluted weighted-average shares
• ORAMED PHARMACEUTICALS INC.: basic earnings per share
• ORAMED PHARMACEUTICALS INC.: diluted earnings per share
• ORAMED PHARMACEUTICALS INC.: income tax expense or benefit
• ORAMED PHARMACEUTICALS INC.: net property, plant and equipment
• ORAMED PHARMACEUTICALS INC.: share-based compensation expense
• ORAMED PHARMACEUTICALS INC.: operating income or loss
• ORAMED PHARMACEUTICALS INC.: current assets
• ORAMED PHARMACEUTICALS INC.: current liabilities
• ORAMED PHARMACEUTICALS INC.: current accounts payable
• ORAMED PHARMACEUTICALS INC.: cost of revenue
• ORAMED PHARMACEUTICALS INC.: research and development expense
• ORAMED PHARMACEUTICALS INC.: common shares outstanding
• ORAMED PHARMACEUTICALS INC.: cash including restricted cash
• ORAMED PHARMACEUTICALS INC.: additional paid-in capital
• ORAMED PHARMACEUTICALS INC.: accumulated other comprehensive income or loss
• ORAMED PHARMACEUTICALS INC.: total equity including noncontrolling interests
• ORAMED PHARMACEUTICALS INC.: operating lease right-of-use asset
• ORAMED PHARMACEUTICALS INC.: operating lease liability
• ORAMED PHARMACEUTICALS INC.: long-term debt
• ORAMED PHARMACEUTICALS INC.: gross property, plant and equipment
• ORAMED PHARMACEUTICALS INC.: accumulated depreciation on property, plant and equipment
• ORAMED PHARMACEUTICALS INC.: other noncurrent assets
• ORAMED PHARMACEUTICALS INC.: other noncurrent liabilities
• ORAMED PHARMACEUTICALS INC.: accrued current liabilities
• ORAMED PHARMACEUTICALS INC.: prepaid expenses and other current assets
• ORAMED PHARMACEUTICALS INC.: pre-tax income or loss from continuing operations
• ORAMED PHARMACEUTICALS INC.: profit or loss including noncontrolling interests
• ORAMED PHARMACEUTICALS INC.: comprehensive income or loss
• ORAMED PHARMACEUTICALS INC.: net income available to common stockholders
• ORAMED PHARMACEUTICALS INC.: general and administrative expense
• ORAMED PHARMACEUTICALS INC.: depreciation, depletion and amortization
• ORAMED PHARMACEUTICALS INC.: other nonoperating income or expense
• ORAMED PHARMACEUTICALS INC.: nonoperating income or expense
• ORAMED PHARMACEUTICALS INC.: current income tax expense or benefit
• ORAMED PHARMACEUTICALS INC.: income taxes paid, net
• ORAMED PHARMACEUTICALS INC.: proceeds from issuing common stock
• ORAMED PHARMACEUTICALS INC.: change in accounts payable

Inspect the source

Entity

ORAMED PHARMACEUTICALS INC. / CIK 0001176309

Captured

2026-09-20T07:44:51.277Z

SEC response SHA-256

4de2fa61f6e99a9334450df93c3a54e105e138fae12a8b631b4bdc95f4c98422

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Latest-filed annual-report facts per unit and reporting period at capture time. Duration facts cover 300 to 400 days. This selection can include restatements and is not a point-in-time backtest dataset. Missing concepts are omitted, never zero-filled. Values retain original units and are not currency converted. Extended concepts require compatible unit shapes and at least three reporting ends with changing values within one unit. Constant or incompatible added histories are omitted.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

• Get an API key and run your first validation
• Connect the MCP server to your coding assistant
• Inspect the ALPHAC engine on GitHub
• Read the MCP server source and integration examples

import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001176309.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))